EP3324981A1 - Nouvelle utilisation d'acide hyaluronique - Google Patents
Nouvelle utilisation d'acide hyaluroniqueInfo
- Publication number
- EP3324981A1 EP3324981A1 EP16750610.4A EP16750610A EP3324981A1 EP 3324981 A1 EP3324981 A1 EP 3324981A1 EP 16750610 A EP16750610 A EP 16750610A EP 3324981 A1 EP3324981 A1 EP 3324981A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hyaluronic acid
- crosslinked
- use according
- periosteum
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 60
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 59
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 59
- 208000006735 Periostitis Diseases 0.000 claims abstract description 19
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 19
- 210000003460 periosteum Anatomy 0.000 claims abstract description 19
- 210000001519 tissue Anatomy 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims abstract description 4
- 239000000499 gel Substances 0.000 claims description 15
- 210000002379 periodontal ligament Anatomy 0.000 claims description 9
- 239000008363 phosphate buffer Substances 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 230000035876 healing Effects 0.000 claims description 5
- 230000008929 regeneration Effects 0.000 claims description 5
- 238000011069 regeneration method Methods 0.000 claims description 5
- HPILSDOMLLYBQF-UHFFFAOYSA-N 2-[1-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COC(CCC)OCC1CO1 HPILSDOMLLYBQF-UHFFFAOYSA-N 0.000 claims 1
- 239000007924 injection Substances 0.000 description 18
- 238000002347 injection Methods 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 9
- 239000012736 aqueous medium Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241001573498 Compacta Species 0.000 description 1
- 208000010138 Diastema Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101710128038 Hyaluronan synthase Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 229920001954 Restylane Polymers 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000000475 diastema Anatomy 0.000 description 1
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C19/00—Dental auxiliary appliances
- A61C19/06—Implements for therapeutic treatment
- A61C19/063—Medicament applicators for teeth or gums, e.g. treatment with fluorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2817—Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]
Definitions
- the invention relates to a novel use of a hyaluronic acid in gels crosslinked or in a mixture of crosslinked and uncrosslinked form.
- Hyaluronic acid or hyaluronan a glucosaminoglycan
- ECM extracellular matrix
- CNS central nervous system
- HA is a polymer consisting of monomeric structural units of the disaccharide of D-glucuronic acid and N-acetyl-D-glucosamine which are polymerized in the body of vertebrates of HA synthases.
- the chain length of the polymer typically comprises 250 to 50,000 disaccharide units, which corresponds to a molecular weight of about 95 kD to about 19,000 kD.
- HA has an exceptionally high water binding capacity (up to 6 1 water per 1 g HA) and viscoelasticity, which forms the basis for its importance as a structural component.
- HA Because of its complex interactions with matrix components and cells because of their physicochemical and biological properties, HA also plays a very diverse role in physiological events, which has not yet been fully elucidated.
- Some important properties besides the structural properties of HA are a fibroblast activating property in the skin, a significant bacteriostatic effect of high and medium molecular weight HA, an angiogenic effect of low molecular weight HA, and surprisingly an anti-angiogenic effect of high molecular weight HA osteogenic effect.
- non-animal biotechnological recombinant HA is currently used in uncrosslinked or partially crosslinked form, especially for injection into the joint space of arthritic joints, in dentistry for injection into the periodontal ligament, in hydrogels for wound care Nasal sprays and eye drops, used for wrinkle injection, modeling of lips and other body shaping.
- Cosmetics mainly use degradation fragments of HA with a relatively low molecular weight (eg 50 to 130 kD).
- the object of the invention was to improve the efficacy of hyaluronic acid in bone-near tissues and possibly in the bone itself by a suitable supply of hyaluronic acid.
- the invention relates to the use of a hyaluronic acid-containing gel for healing and / or regenerating bone and bone surrounding tissue in humans or a vertebrate by injecting the hyaluronic acid in crosslinked form or in a mixture of crosslinked and uncrosslinked gels into the periosteum of a bone ,
- FIG. 1 shows schematically the injection of hyaluronic acid into the periosteum of a
- Figure 2 shows schematically the injection of hyaluronic acid into the periodontal ligament.
- hyaluronic acid (HA) used in this invention may be either in crosslinked form or in a mixture of uncrosslinked and crosslinked form.
- the uncrosslinked form of HA preferably used herein has a molecular weight in the range of about 730 kD to about 1,500 kD.
- Crosslinked forms of FIA are commercially available in large numbers. They are generally injected in aqueous solution as a gel. Basically, a distinction is made between particulate cross-linked HA and large particles, for example in the range from a few ⁇ m to about 1000 ⁇ m, and homogeneous, nonparticular crosslinked monophasic HA, although this difference may not be as important in practice as often assumed. Numerous cross-linked HA products have been developed, especially for use as dermal fillers. Chain lengths and crosslinking agents can vary widely.
- Chain length distribution (relatively short chains and long chains), the latter being able to form an interpenetrating network after crosslinking.
- the chain length is generally 1,000 to 3,000 kD, but in some cases may be lower or higher.
- Common crosslinking agents are e.g. Glutaraldehyde, 1-ethyl-3- (3-dimethylaminoproyl) carbodiimide (EDC), poly (ethylene glycol) diglycidyl ether (EX 801), divinylsulfone (DVS), 1, 4-butanediol diglycidyl ether (BDDE) and 1, 2, 7, 8 -Diepoxyoctan.
- EDC 1-ethyl-3- (3-dimethylaminoproyl) carbodiimide
- EX 801 poly (ethylene glycol) diglycidyl ether
- DVD divinylsulfone
- BDDE 4-butanediol diglycidyl ether
- 1, 2, 7, 8 -Diepoxyoctan 1, 2, 7, 8 -Diepoxyoctan.
- Crosslinked HA is used in an aqueous medium in gel form.
- concentration of crosslinked HA in the aqueous medium will generally vary in commercially available products from about 18 to about 26 mg of crosslinked HA / ml aqueous medium, e.g. a phosphate buffer.
- the ratio (w / v) of hyaluronic acid to aqueous medium, e.g. Phosphate buffer ranging from 1:35 to 1:45.
- the gel used according to the invention may contain further drugs or adjuvants, such as preservatives or other auxiliaries customary in pharmacy.
- Some common commercial cross-linked HA products for use as dermal fillers include Restylane ® (Fa. Galderma), Juvederm ® (Fa. Allergan), Belotero ® (Fa. Merz), Hyal ® (Fa. Merz).
- Fa. Galderma Stylage ® (Fa. Laboraitres Vivacy) Puragen ® (Fa. Menotr Corporation), Emervel ® and Teosyal ® (Fa. Laboratoires Teoxane).
- Periosyal ® (Laboratoires Teoxane) is used especially in dentistry.
- the periosteum is a highly vascular connective tissue that surrounds all but the articular and muscular attachments. Its thickness is generally about 0.070 to 0.150 mm. It comprises at least two layers, an inner cambium layer and an outer fiber layer.
- the inner layer contains numerous osteoblasts and osteogenic progenitor cells, the outer layer is composed of dense collagen fiber, fibroblasts and their progenitor cells.
- a monophasic gel preparation with crosslinked HA or a gel preparation of crosslinked PIA with very small particles in the range up to the highest 20 ⁇ m is preferred, which may optionally also contain uncrosslinked HA.
- a preferred product is, for example, with 5.0 to 10.0 wt .-% 1, 4-butanediol diglycidyl ether (BDDE) crosslinked HA shorter chain length with a concentration of 25 mg HA in phosphate buffer pH 7.3 ad 1 ml (commercially available as Periosyal ® Fill the company Laboratoires Teoxane) or with 1.9 to 4.0 wt .-% 1, 4-butanediol diglycidyl ether (BDDE) crosslinked HA long
- Injection of the HA preparation into the periosteum is performed with a thin pointed needle preferably having an outside diameter of 0.30 - 0.50 mm (EN ISO 9626) or an electronic pen needle of similar diameter.
- the needle is slowly introduced to the bone, until a resistance of Kompakta is no longer surmountable.
- the preparation is slowly added e.g. in the course of 10 seconds to 2 minutes, preferably 20 seconds to 60 seconds, pushed through the needle into the periosteum. It is possible that only part of the injected HA preparation remains in the periosteum and excess drug swells into surrounding structures.
- the same or another HA preparation may also be injected into soft tissue surrounding the periosteum of the bone. This too is described in more detail in the following example by means of an injection into the periodontal ligament of teeth.
- the effect of the injection into the periosteum is to heal inflammation in the soft tissue surrounding the concha and in the cooking itself as well as to regenerate these structures, as further described below with reference to an example from the dental field. If necessary, the injection can be done every 1 to 2 weeks, e.g. be repeated once or twice.
- Possible side effects of the injection may be e.g. Swelling, redness, pain, itching and sensitivity at the injection site.
- Hyaluronic acid but there appear to be other factors, as treating the periodontal ligament alone without injection into the periosteum of the alveolar bone did not or only to a lesser extent observe these treatment successes.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Dentistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
Acide hyaluronique sous forme réticulée ou dans un mélange de gel contenant une forme réticulée et une forme non réticulée pour guérir et/ou régénérer des os et du tissu entourant les os, chez l'homme ou un vertébré, par injection du gel contenant l'acide hyaluronique dans le périoste d'un os.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102015009271.5A DE102015009271A1 (de) | 2015-07-19 | 2015-07-19 | Neue Verwendung von Hyaluronsäure |
| PCT/EP2016/001253 WO2017012711A1 (fr) | 2015-07-19 | 2016-07-18 | Nouvelle utilisation d'acide hyaluronique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP3324981A1 true EP3324981A1 (fr) | 2018-05-30 |
Family
ID=56683880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP16750610.4A Withdrawn EP3324981A1 (fr) | 2015-07-19 | 2016-07-18 | Nouvelle utilisation d'acide hyaluronique |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10449214B2 (fr) |
| EP (1) | EP3324981A1 (fr) |
| DE (1) | DE102015009271A1 (fr) |
| WO (1) | WO2017012711A1 (fr) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002504083A (ja) | 1996-03-05 | 2002-02-05 | オーケスト インコーポレイテッド | ヒアルロン酸および増殖因子による骨の増殖を促進する方法 |
| FR2865737B1 (fr) * | 2004-02-03 | 2006-03-31 | Anteis Sa | Gel reticule biocompatible |
| US20050226936A1 (en) * | 2004-04-08 | 2005-10-13 | Q-Med Ab | Method of soft tissue augmentation |
| EP2647649A1 (fr) * | 2012-04-04 | 2013-10-09 | Andreas Witt | Gel d'acide hyaluronique, procédé de fabrication de ce gel et produit médical contenant ce gel |
| WO2014138897A1 (fr) * | 2013-03-14 | 2014-09-18 | Anacoti Ltd. | Dérivés d'acide hyaluronique |
-
2015
- 2015-07-19 DE DE102015009271.5A patent/DE102015009271A1/de not_active Withdrawn
-
2016
- 2016-07-18 US US15/745,744 patent/US10449214B2/en active Active
- 2016-07-18 EP EP16750610.4A patent/EP3324981A1/fr not_active Withdrawn
- 2016-07-18 WO PCT/EP2016/001253 patent/WO2017012711A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017012711A1 (fr) | 2017-01-26 |
| US20180207199A1 (en) | 2018-07-26 |
| DE102015009271A1 (de) | 2017-01-19 |
| US10449214B2 (en) | 2019-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2683286C2 (ru) | Способ поперечного сшивания гиалуроновой кислоты, способ приготовления инъекционного гидрогеля, гидрогель и его применение | |
| DE69902913T2 (de) | Injizierbare zweiphasige zusammensetzungen für kosmetische und plastische chirurgie | |
| DE69520613T2 (de) | Injizierbares Verabreichungssystem für Arzneistoffe auf Kollagen-Basis und seine Verwendung | |
| DE69630253T2 (de) | Füllmaterial für implantierbare Prothesen aus Weichgewebe und Implantate daraus | |
| DE69306114T2 (de) | Verwendung von in situ modifikation von alginat zur vorbeugung von gewebeadhäsion | |
| KR102052775B1 (ko) | 진피 필러 조성물 | |
| DE69227705T2 (de) | Verwendung von vernetztem kollagen zur herstellung einer nähfähigen bioverträglichen langsam resorbierbaren membran | |
| DE69118683T2 (de) | Methylpyrrolidonchitosan, verfahren zu dessen herstellung und seine verwendungen | |
| US10077320B2 (en) | Process for preparing a cross-linked hyaluronic acid product | |
| DE60123225T2 (de) | Clathratekomplexe auf der basis von hyaluronsäurederivaten und deren verwendung als arzneimittel | |
| EP2229190A1 (fr) | Implants en alginate monolithique réticulé in situ | |
| KR20150022934A (ko) | 히알루론산을 기본으로 하는 조성물의 제조 방법 | |
| RU2008137983A (ru) | Биоматериал, включающий его имплантант, вводимый с помощью инъекции, способ его получения и его применение | |
| KR101926751B1 (ko) | 피부 충진용 필러 및 이의 제조방법 | |
| WO1993002699A1 (fr) | Utilisation du collagene pour traiter des processus degeneratifs des articulations | |
| EP1418188B1 (fr) | Hydrogel de polyacrylamide et son utilisation comme endoprothèse | |
| KR20190070327A (ko) | 2가 아연 양이온을 갖는 히알루론산 겔 | |
| EP2647649A1 (fr) | Gel d'acide hyaluronique, procédé de fabrication de ce gel et produit médical contenant ce gel | |
| DE60113874T2 (de) | Verfahren zur wiederherstellung des fettpolsters | |
| DE112022005448T5 (de) | Kationisches Material zur Zahndesensibilisierung sowie dessen Herstellungsverfahren und Verwendung | |
| WO2009021526A1 (fr) | Dispersion d'acide hyaluronique, sa préparation et son application | |
| EP3324981A1 (fr) | Nouvelle utilisation d'acide hyaluronique | |
| WO2019121694A1 (fr) | Compositions injectables d'acide hyaluronique réticulé et de bupivacaïne, et utilisations associées | |
| DE19954357C2 (de) | Zusammensetzung, enthaltend Heteropolysaccharid und perlenförmiges quervernetztes Polysaccharid, sowie deren Verwendung für medizinische/kosmetische Zwecke | |
| MLF et al. | Clinical evaluation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20180219 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20200201 |